Skip to main content

Profiles

TrialSpark

TrialSpark is an American clinical trials company based in New York.

History

On November 29, 2022, TrialSpark announced the formation of Libertas Bio after it had acquired a majority position in a portfolio of immunodermatology assets from Asana BioSciences.[1]

Investors

Investors in TrialSpark include:[2][3][4][5]

  • Anne Wojcicki
  • ArrowMark Partners
  • Casdin Capital
  • Dragoneer Investment Group
  • Felicis
  • John Doerr
  • Lachy Groom
  • Sam Altman
  • Section 32
  • Sequoia Capital
  • Sound Ventures
  • Spark Capital
  • Thrive Capital
  • TQ Ventures

  1. TrialSpark announces acquisition of a clinical-stage immunodermatology portfolio and formation of Libertas Bio. (2022, November 29). BioSpace. https://web.archive.org/web/20230728172436/https://www.biospace.com/article/releases/trialspark-announces-acquisition-of-a-clinical-stage-immunodermatology-portfolio-and-formation-of-libertas-bio/ ↩︎

  2. TrialSpark - Funding, Financials, Valuation & Investors. Crunchbase. Retrieved July 28, 2023, from https://www.crunchbase.com/organization/trialspark/company_financials ↩︎

  3. Venture Round - TrialSpark - 2018-10-15 - Crunchbase Funding Round Profile. Crunchbase. Retrieved July 28, 2023, from https://www.crunchbase.com/funding_round/trialspark-series-unknown--abcf16de ↩︎

  4. Series C - TrialSpark - 2021-09-30 - Crunchbase Funding Round Profile. Crunchbase. Retrieved July 28, 2023, from https://www.crunchbase.com/funding_round/trialspark-series-c--bcfe174f ↩︎

  5. Bloomberg. (2021, September 30). Startup with $120 million for deals aims to make drugs cheaply. Mint. http://archive.today/2023.07.28-234253/https://www.livemint.com/companies/start-ups/trialspark-with-120-million-for-deals-aims-to-make-drugs-cheaply-11633008141507.html ↩︎